Allogene has announced plans to expand development of the next generation of CAR-T therapies after securing $120m in financing. The investment was led by Perceptive Advisors, with further contributions from a range of partners including Deerfield Management, Fidelity Management and Research, Franklin Templeton Investments, Jennison Associates and Surveyor Capital. “Today’s announcement is an important milestone for our company as we continue to move forward on this promising new therapy,” said Dr. David L. Goldstein, CEO of Allogene. The new investment comes after the company, which was launched in April, secured $300 million in series A funding.
Allogene has announced plans to expand development of the next generation of CAR-T therapies after securing $120m in financing. The investment was led by Perceptive Advisors, with further contributions from a range of partners including Deerfield Management, Fidelity Management and Research, Franklin Templeton Investments, Jennison Associates and Surveyor Capital. The company is working on allogeneic CAR-T therapies, which are made with donor cells designed for use in multiple patients rather than those tailored for specific individuals using their own cells. The new investment comes after the company, which was launched in April, secured $300 million in series A funding.